NCT04223232View on ClinicalTrials.gov

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

January 22, 2020

Study Completion Date

January 22, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

[14C]-MD1003

single oral dose of 100mg \[14C\]-MD1003

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

MedDay Pharmaceuticals SA

INDUSTRY

NCT04223232 - Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter